The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 601–700 of 1,039
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A. J., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A. D., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214788 · Cited by 154
Self-citationOpzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 155
Antigen processing and presentation in cancer immunotherapy
Lee, M. Y., Jeon, J. W., Sievers, C. M., & Allen, C. T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001111 · Cited by 154
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
Chhabra, N., & Kennedy, J. M. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00833-8 · Cited by 155
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Liu, J., Zhao, Z., Qiu, N., Zhou, Q., Wang, G., Jiang, H., Piao, Y., Zhou, Z., Tang, J., & Shen, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-22407-6 · Cited by 154
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153
Lugowska, I. A., Teterycz, P., & Rutkowski, P. L. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73889 · Cited by 152
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Wang, F., Xu, D., Su, H., Zhang, W., Sun, X., Monroe, M. K., Chakroun, R. W., Wang, Z., Dai, W., Oh, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz8985 · Cited by 152
Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer
Gao, Y., Shi, S., Ma, W., Chen, J., Cai, Y., Ge, L., Li, L., Wu, J., & Tian, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.045 · Cited by 151
Mehnert, J. M., Bergsland, E. K., O’Neil, B. H., Santoro, A., Schellens, J. H. M., Cohen, R. B., Doi, T., Ott, P. A., Pishvaian, M. J., Puzanov, I. J., et al. (2020) · Cancer · doi:10.1002/cncr.32883 · Cited by 151
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 151
Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 150
Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V., de Groot, J., Glitza, I. C., Herlyn, M., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12538 · Cited by 150
Targeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 150
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 149
Self-citationLi, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 149
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 151
Schreuer, M. S., Meersseman, G., Herrewegen, S. V. D., Jansen, Y. J. L., Chevolet, I., Bott, A., Wilgenhof, S., Seremet, T., Jacobs, B., Buyl, R., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0852-6 · Cited by 148
Self-citationAtkins, M. B., Clark, J. I., & Quinn, D. I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx151 · Cited by 148
He, Y., Lei, L., Cao, J., Yang, X., Cai, S., Tong, F., Huang, D., Mei, H., Luo, K., Gao, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.aba0776 · Cited by 148
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 156
Migliorini, D., Dutoit, V., Allard, M., Grandjean Hallez, N., Marinari, E., Widmer, V., Philippin, G., Corlazzoli, F., Gustave, R., Kreutzfeldt, M., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz040 · Cited by 147
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2016) · Future Oncology · doi:10.2217/fon.15.222 · Cited by 147
Li, H., Yu, J., Liu, C., Liu, J., Subramaniam, S., Zhao, H., Blumenthal, G. M., Turner, D. C., Li, C. H., Ahamadi, M., et al. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9528-y · Cited by 147
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Joller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 145
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
van Willigen, W. W., Bloemendal, M., Gerritsen, W. R., Schreibelt, G., de Vries, I. J. M., & Bol, K. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02265 · Cited by 145
Nixon, N. A., Blais, N., Ernst, S., Kollmannsberger, C., Bebb, G. D., Butler, M. O., Smylie, M., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.3840 · Cited by 145
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 144
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Morrison, C., Pabla, S., Conroy, J. M., Nesline, M., Glenn, S. T., Dressman, D. C., Papanicolau‐Sengos, A., Burgher, B., Andreas, J., Giamo, V., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0344-8 · Cited by 143
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 143
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Self-citationCheckpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Tsang, V., McGrath, R. T., Clifton-Bligh, R. J., Scolyer, R. A., Jakrot, V., Guminski, A. D., Long, G. V., & Menzies, A. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00423 · Cited by 143
Self-citationOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Long, G. V., Hodi, F. S., Lipson, E. J., Schadendorf, D., Ascierto, P. A., Matamala, L., Salman, P., Gutiérrez, E. C., Rutkowski, P. L., Gogas, H. J., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200239 · Cited by 142
Self-citationPai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
Self-citationCombination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 141
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 142
NK Cell-Based Immunotherapies in Cancer
Shin, M. H., Kim, J., Lim, S. A., Kim, J. H., Kim, S., & Lee, K. (2020) · Immune Network · doi:10.4110/in.2020.20.e14 · Cited by 141
Intratumoral Immunotherapy: From Trial Design to Clinical Practice
Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, É., Massard, C., Robert, C., Ammari, S., de Baère, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0473 · Cited by 141
Self-citationWang, Z., Kang, W.-T., Li, O., Qi, F., Wang, J., You, Y., He, P., Suo, Z., Zheng, Y., & Liu, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.005 · Cited by 141
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Fabbi, M., Carbotti, G., & Ferrini, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/3958069 · Cited by 140
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 140
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis
Mounier, N. M., Abdel-Maged, A. E.-S., Wahdan, S. A., Gad, A. M., & Azab, S. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118071 · Cited by 139
Evolution of delayed resistance to immunotherapy in a melanoma responder
Liu, D., Lin, J., Robitschek, E. J., Kasumova, G. G., Heyde, A., Shi, A., Kraya, A., Zhang, G., Moll, T. O. C., Frederick, D. T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01331-8 · Cited by 139
Shirai, T., Sano, T., Kamijo, F., Saito, N., Miyake, T., Kodaira, M., Katoh, N., Nishie, K., Okuyama, R., & Uhara, H. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv158 · Cited by 138
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 144
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
Iribarren, K., Bloy, N., Buqué, A., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1088631 · Cited by 137
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Luen, S. J., Savas, P. S., Fox, S. B., Salgado, R., & Loi, S. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.010 · Cited by 137
Wong, A. N. M., McArthur, G. A., Hofman, M. S., & Hicks, R. J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3691-7 · Cited by 137
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 137
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 137
Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 138
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Kim, H. S., Lee, J. Y., Lim, S. H., Park, K., Sun, J., Ko, Y. H., Baek, C., Son, Y., Jeong, H. S., Ahn, Y. C., et al. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2015.249 · Cited by 136
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 136
Seban, R., Nemer, J. S., Marabelle, A., Yeh, R., Deutsch, É., Ammari, S., Moya‐Plana, A., Mokrane, F., Gartrell, R. D., Finkel, G. G., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04411-7 · Cited by 136
Self-citationImbert, C., Montfort, A., Fraisse, M., Marcheteau, E., Gilhodes, J., Martin, E., Bertrand, F. A., Marcellin, M., Burlet‐Schiltz, O., de Peredo, A. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14218-7 · Cited by 136
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yang, T., Kong, Z., & Ma, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1782692 · Cited by 137
Long, G. V., Carlino, M. S., McNeil, C. M., Ribas, A., Gaudy‐Marqueste, C., Schachter, J., Nyakas, M., Kee, D., Petrella, T. M., Blaustein, A. S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2330 · Cited by 136
Self-citationMetastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 135
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 135
Tumor intrinsic and extrinsic immune functions of CD155
O’Donnell, J. S., Madore, J., Li, X.-Y., & Smyth, M. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.013 · Cited by 135
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 135
Bieber, K., Hundt, J. E., Yu, X., Ehlers, M., Petersen, F., Karsten, C. M., Köhl, J., Kridin, K., Kalies, K., Kasprick, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103236 · Cited by 135
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 143
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Baruch, E. N., Gleber‐Netto, F. O., Nagarajan, P., Rao, X., Akhter, S., Eichwald, T., Xie, T., Balood, M., Adewale, A., Na’ara, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09370-8 · Cited by 135
Jour, G., Glitza, I. C., Ellis, R. M., Torres-Cabala, C. A., Tetzlaff, M. T., Li, J. Y., Nagarajan, P., Huen, A., Aung, P. P., Ivan, D. S., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12717 · Cited by 134
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., & Berardi, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.002 · Cited by 134
Lévy, A., Massard, C., Soria, J., & Deutsch, É. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.013 · Cited by 134
Review of cancer treatment with immune checkpoint inhibitors
Thallinger, C., Füreder, T., Preusser, M., Heller, G., Müllauer, L., Höeller, C., Prosch, H., Frank, N., Świerzewski, R., Berger, W., et al. (2017) · Wiener klinische Wochenschrift · doi:10.1007/s00508-017-1285-9 · Cited by 134
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 134
Tumor-on-chip modeling of organ-specific cancer and metastasis
Piccolo, N. D., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 134
Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 134
Self-citationTumor‐infiltrating lymphocytes for the treatment of metastatic cancer
Foppen, M. H. G., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 133
Wirsdörfer, F., de Leve, S., & Jendrossek, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010024 · Cited by 133
Fu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 133
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Clinical and translational attributes of immune-related adverse events
Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F., & Eggermont, A. M. M. (2024) · Nature Cancer · doi:10.1038/s43018-024-00730-3 · Cited by 136
Bowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 132
Self-citationGomez‐Roca, C., Cassier, P. A., Zamarin, D., Machiels, J., Perez‐Gracia, J. L., Hodi, F. S., Taus, Á., Martinez‐García, M., Boni, V., Eder, J. P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004076 · Cited by 134
Harrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 131
Guan, J., Lim, K. S., Mekhail, T. M., & Chang, C.-C. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0361-ra · Cited by 131
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 131
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
Kao, J. C., Brickshawana, A., & Liewluck, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0878-7 · Cited by 133
Hecht, M., Büttner-Herold, M. J., Erlenbach‐Wünsch, K., Haderlein, M., Croner, R. S., Grützmann, R., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.015 · Cited by 130
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
Forsberg, E. M. V., Lindberg, M. F., Jespersen, H., Alsén, S., Bagge, R. O., Donia, M., Svane, I. M., Nilsson, O., Ny, L., Nilsson, L. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3158 · Cited by 132
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 130
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Johnson, R. M. G., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 131
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 129
Hong, X., Sullivan, R. J., Kalinich, M., Kwan, T. T., Giobbie‐Hurder, A., Pan, S., LiCausi, J. A., Milner, J. D., Nieman, L. T., Wittner, B. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719264115 · Cited by 129
Wagner, N. B., Forschner, A., Leiter, U., Garbe, C., & Eigentler, T. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0167-x · Cited by 129
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 129
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies
Liu, Y., Guo, J., & Huang, L. (2020) · Theranostics · doi:10.7150/thno.42998 · Cited by 129
Dimitriou, F., Hogan, S. A., Menzies, A. M., Dummer, R., & Long, G. V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.031 · Cited by 129
Self-citationPrinciples of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 128
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
